As for Novavax's looming third-quarter update, there's really no way to know whether or not the company will announce anything that's unsettling. Actually, its management team should have a positive message considering that it has delivered thus far on the most recent timeline for completing regulatory filings for its COVID-19 vaccine, NVX-CoV2373.